At Kamm McKenzie, we offer fetal screening tests in the first and second trimesters to all of our
patients. One test that I have found raises a great deal of confusion is the blood test for alpha
fetoprotein (AFP). In the past, AFP was used as one of multiple markers in the Quad and Tetra
screens which evaluated for the likelihood of chromosomal abnormalities such as Down’s
syndrome. Now, we almost universally screen for chromosomal abnormalities with cell-free DNA
(cfDNA) testing. With the widespread use of cfDNA, we now use AFP on its own for a different screening indication – to assess the risk of fetal structural or anatomic defects.